Atlanta MACS/WIHS Combined Cohort Study Clinical Research Site

亚特兰大 MACS/WIHS 联合队列研究临床研究网站

基本信息

批准号：
9903478
负责人：
Ighovwerha Ofotokun
金额：
$ 294.09万
依托单位：
EMORY UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-04-01 至 2026-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/9903478
关键词：
Advisory Committees Affect Ancillary Study Award Biological Career Mobility Caring Clinic Clinical Clinical Research Cohort Studies Communities Community Outreach Consent Data Databases Development Enrollment Environment Epidemic Event Faculty Fostering Foundations Funding Funding Agency Goals Growth HIV HIV Seronegativity HIV Seropositivity HIV diagnosis Health Home environment Individual K-Series Research Career Programs Laboratory Study Lead Leadership Link Location Mediation Mentorship Minority Groups Operations Research Participant Pathogenesis Patients Pharmacologic Substance Population Heterogeneity Principal Investigator Procedures Productivity Protocols documentation Publications Quality Control Reading Research Research Activity Research Infrastructure Research Personnel Resources Risk Role Rural SECTM1 gene Science Scientist Site Specimen Structure Training Underrepresented Minority United States National Institutes of Health Visit Woman adjudication age related base career development clinical research site cohort comorbidity data quality disease registry good laboratory practice health disparity innovative technologies men men who have sex with men multidisciplinary next generation programs recruit volunteer

项目摘要

Abstract The overarching goal of the Atlanta Clinical Research Site (CRS) is to advance the unified scientific agenda of the MACS/WIHS CCS by: a) providing leadership in the development of the unified science protocols; b) serving as a local reading center and support laboratory for studies; and c) leveraging our research infrastructure to implement the CCS protocols by retaining current participants, recruiting new participants from under-represented minority groups, and engaging Emory scientists and the local community in CCS science and activities. The Atlanta CRS is well poised to accomplish these goals because of our unique location at the epicenter of the U.S. epidemic, the robustness of our HIV research program, and our track record of successful and collaborative contribution to the unified science of the WIHS over the past 5 years. Georgia now has the third highest rate of new HIV diagnoses among the Southern states1 and the 5th largest HIV epidemic among the U.S. states2. While HIV rates are high in both rural and urban Georgia, Atlanta is home to most (62%) of the state’s affected patients, and the majority reside within 10 miles of the Atlanta CRS. Importantly, nearly two-thirds of people living with HIV in Atlanta and ~20% in Georgia receive care in Emory associated HIV clinics (n=10,354). HIV+ and negative volunteers that have consented to be contacted for research are available via the CFAR HIV Disease Registry (> 13,000 unique patients), the PRISM Health MSM cohorts led by Emory faculty Dr. Patrick Sullivan, and the Georgia CTSA database (>100,000 individuals), providing us access to a diverse population of HIV+ and at-risk HIV- individuals from across the state. Leveraging these institutional resources, the Atlanta CRS will contribute to the CCS unified science in the following manner: 1) Provide leadership to support the CCS unified specific aims through expert contribution by Emory investigators, including scientific specific leadership roles in the following aims: (a) age related co- morbidities; (b) health disparities; (c) HIV pathogenesis; and (d) career development; 2) Leverage our state-of- the-art research infrastructure to implement all components of the CCS unified science, including adjudication of clinical events, development of data quality control procedures and good laboratory practices, staff training in relevant CCS research activities, and enrollment of new participants; 3) Enhance our vibrant community engagement to support our efforts to enroll new participants, expand our CAB to be representative of the combined cohort of women and men, and introduce use of innovative technology to enhance community outreach and support accrual and engagement of our combined cohort; and 4) Build on our track record of mentorship by expanding HIV research opportunities for early stage investigators in coordination with the CCS Investigator Developmental Award Advisory Committee.

抽象的亚特兰大临床研究中心 (CRS) 的总体目标是推进统一的科学议程 MACS/WIHS CCS： a) 领导统一科学协议的制定；充当当地的阅读中心和研究支持实验室；c) 利用我们的研究；通过保留现有参与者、招募新参与者来实施 CCS 协议的基础设施代表性不足的少数群体，并让埃默里大学的科学家和当地社区参与 CCS 科学由于我们在亚特兰大的独特地理位置，亚特兰大 CRS 已经做好了实现这些目标的准备。美国艾滋病流行的震中、我们艾滋病毒研究计划的稳健性以及我们的成功记录过去 5 年对 WIHS 统一科学的合作贡献。佐治亚州目前的艾滋病毒新诊断率在南部各州1中排名第三，在南部各州中排名第五美国各州的艾滋病毒流行情况2 虽然佐治亚州农村和城市的艾滋病毒感染率都很高，但亚特兰大的艾滋病毒感染率却很高。该州大多数 (62%) 受影响患者的住所，其中大多数居住在亚特兰大 CRS 10 英里范围内。重要的是，亚特兰大近三分之二的艾滋病毒感染者和佐治亚州约 20% 的艾滋病毒感染者在埃默里接受护理相关的艾滋病毒诊所（n=10,354），同意联系艾滋病毒阳性和阴性志愿者。研究可通过 CFAR HIV 疾病登记处（超过 13,000 名独特患者）、PRISM Health MSM 获得由埃默里大学教职员工 Patrick Sullivan 博士领导的队列和佐治亚州 CTSA 数据库（>100,000 人），使我们能够接触到全州不同的艾滋病病毒感染者和高危艾滋病毒感染者。利用这些机构资源，亚特兰大 CRS 将为 CCS 统一科学做出贡献以下方式： 1) 通过专家贡献提供领导支持 CCS 统一的具体目标埃默里大学的研究人员，包括在以下目标中发挥科学特定的领导作用：（a）与年龄相关的合作发病率；(b) 健康差异；(c) 艾滋病毒发病机制；(d) 职业发展；最先进的研究基础设施，用于实施 CCS 统一科学的所有组成部分，包括裁决临床事件、数据质量控制程序和良好实验室规范的制定、员工培训相关 CCS 研究活动以及新参与者的招募； 3) 增强我们充满活力的社区；参与以支持我们招收新参与者的努力，扩大我们的 CAB 以代表结合女性和男性群体，并引入创新技术来增强社区外展和支持我们合并群体的累积和参与；以及 4) 建立在我们的跟踪记录的基础上与 CCS 协调，为早期研究人员扩大艾滋病毒研究机会，提供指导研究者发展奖咨询委员会。